CSTL vs PATH · rev $332.1M vs P/E 19, rev $1.61B
Castle Biosciences Inc (CSTL) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Castle Biosciences Inc (CSTL) is a diagnostics & research company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported CSTL revenue for 2024-12-31 was $332.1M. Net income was $18.2M. Revenue was up 51.1% from 2023-12-31 to 2024-12-31. CSTL currently screens at market cap $570.2M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
CSTL currently screens at market cap $570.2M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the CSTL and PATH stock pages for the full models.
Not investment advice.